Inflammation and itching in patients suffering from atopic dermatitis and psoriasis. Assessment of the expression of neurotrophins аnd neuropeptides

Cover Page

Abstract


Goal. To assess the expression of neurotrophin, a nerve growth factor, amphiregulin, an epidermal growth factor, semaphorin 3A, a nerve repulsion factor, and PGP9.5 protein, a nerve fiber marker, in the skin of patients suffering from atopic dermatitis and psoriasis. Materials and methods. The study involved 30 patients suffering from atopic dermatitis and 30 patients suffering from psoriasis vulgaris. The disease severity was assessed by SCORAD and PASI. The extent of itching was assessed by the visual analogue scale. The expression of amphiregulin, semaphorin 3A (a nerve growth factor) and PGP9.5 protein (a nerve fiber marker) in the skin of patients was assessed by the indirect immunofluorescence method. Quantitative parameters of their expression were assessed by using the basic pack of the Olympus Fluoview software, Ver. 1.7b. Results. Increased epidermal innervation was revealed in the patients suffering from atopic dermatitis and psoriasis, which demonstrates an increased skin production of anti-inflammatory neuropeptides and reduced itching sensitivity threshold. A positive correlation between the itching extent and skin expression of neurotrophin (a nerve growth factor) was revealed in the patients with atopic dermatitis. In patients with severe psoriasis, an increased skin expression of amphiregulin, an epidermal growth factor, was discovered. Conclusion. These data demonstrate a pathogenic value of neurotrophin, a nerve growth factor, for the development of itching in patients with atopic dermatitis and amphiregulin in case of psoriasis vulgaris.

V. A. Smolyannikova

I.M. Sechenov First Moscow State Medical University

Author for correspondence.
Email: noemail@neicon.ru

Russian Federation

A. A. Kubanova

State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian Federation

Email: noemail@neicon.ru

Russian Federation

V. V. Chikin

State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian Federation

Email: chikin@cnikvi.ru

Russian Federation

A. E. Karamova

State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian Federation

Email: noemail@neicon.ru

Russian Federation

  1. Guttman-Yassky E., Nograles K.E., Krueger J.G. Contrasting pathogenesis of atopic dermatitis and psoriasis - Part I. Clinical and pathologic concepts. J Allergy Clin Immunol 2011; 127: 1110-1118.
  2. Lowes M.A., Suarez-Farinas M., Krueger J.G. Immunology of psoriasis. Annu. Rev. Immunol. 2014; 32: 227-255. Литература
  3. Ryan C., Korman N.J., Gelfand J.M. Research gaps in psoriasis: opportunities for future studies. J Am Acad Dermatol 2014: 70 (1): 146-167.
  4. Boguniewicz M., Leung D.Y. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev. 2011; 242 (1): 233-246.
  5. Lewin J., Friedlander S.F., Del Rosso J.Q. Atopic dermatitis and the stratum corneum: part 3: the immune system in atopic dermatitis. J Clin Aesthet Dermatol. 2013; 6 (12): 37-44.
  6. Vega J.A., Garcia-Suarez O., Hannestad J. et al. Neurotrophins and the immune system. J Anat 2003; 203: 1-19.
  7. Peters E.M., Ericson M.E., Hosoi J. et al. Neuropeptide control mechanisms in cutaneous biology: physiological and clinical significance. J Invest Dermatol 2006; 126: 1937-1947.
  8. Franco R., Pacheco R., LLuis C. et al. The emergence of neurotransmitters as immune modulators. Trends Immunol 2007; 28 (9): 400-407.
  9. Lotti T., D’Erme A.M., Hercogova J. The role of neuropeptides in the control of regional immunity. Clin Dermatol 2014; 32: 633-645.
  10. Tominaga M., Takamori K. An update on peripheral mechanisms and treatments of itch. Biol Pharm Bull 2013; 36 (8): 1241-1247.
  11. Jackson P., Thomson V.M., Thompson R.J. A comparison of the evolutionary distribution of the two neuroendocrine markers, neuronespecific enolase and protein gene product 9.5. J Neurochem 1985; 45: 185-190.
  12. Day I.N., Thompson R.J. Molecular cloning of cDNA coding for human PGP 9.5 protein. A novel cytoplasmic marker for neurones and neuroendocrine cells. FEBS Lett, 1987; 210: 157-160.
  13. Wilkinson K.D., Lee K.M., Deshpande S. et al. The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science 1989; 246: 670-673.
  14. Day I.N. Enolases and PGP9.5 as tissue-specific markers. Biochem Soc Trans 1992; 20, 637-642.
  15. Day I.N., Thompson R.J. UCHL1 (PGP 9.5): Neuronal biomarker and ubiquitin system protein. Prog Neurobiol 2010; 90: 327-362.
  16. Hershko A., Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998; 67: 425-479.
  17. Wilkinson K.D. Roles of ubiquitinylation in proteolysis and cellular regulation. Ann Rev Nutr 1995; 15: 161-189.
  18. Kabuta T., Mitsui T., Takahashi M. et al. Ubiquitin C-terminal hydrolase L1 (UCH-L1) acts as a novel potentiator of cyclin-dependent kinases to enhance cell proliferation independently of its hydrolase activity.
  19. Катунина О.Р., Чикин В.В., Знаменская Л.Ф., Иноятова Л.А. Роль нейромедиаторов в развитии воспаления в коже больных атопическим дерматитом. Вестн дерматол венерол 2013, (5): 91-101.

Views

Abstract - 81

PDF (Russian) - 21

Refbacks

  • There are currently no refbacks.

Copyright (c)



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies